Citations

Clear

3042 citation(s) found for "Kumar, S".

Autoimmune Lymphoproliferative Syndrome: A Rare Cause of Disappearing HDL Syndrome
Sriram, Swetha, Joshi, Avni Y. , Rodriguez, Vilmarie , Kumar, Seema

Mayo Clinic

Case Reports in Immunology | August 8, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-4

10.1155/2016/7945953 | PMID 27579193 Get It

The term disappearing HDL syndrome refers to development of severe high density lipoprotein cholesterol (HDL-C) deficiency in noncritically ill patients with previously normal HDL-C and triglyceride levels. Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of the immune system due to an inability to regulate lymphocyte homeostasis resulting in lymphadenopathy and hepatosplenomegaly. We describe a 17-year-old boy who was evaluated in the lipid clinic for history of undetectable or low HDL-C and low density lipoprotein cholesterol (LDL-C) levels. Past medical history was significant for ALPS IA diagnosed at 10 years of age when he presented with bilateral cervical adenopathy. He was known to have a missense mutation in one allele of the FAS protein extracellular domain consistent with ALPS type 1A. HDL-C and LDL-C levels had been undetectable on multiple occasions, though lipids had not been measured prior to the diagnosis of ALPS. He had been receiving sirolimus for immunosuppression. The HDL-C and LDL-C levels correlated with disease activity and improved to normal levels during times when the activity of ALPS was controlled. This case highlights the importance of considering ALPS as a cause of low HDL-C and LDL-C levels in a child with evidence of lymphoproliferation.
Outcomes of patients with renal monoclonal immunoglobulin deposition disease
Kourelis, Taxiarchis , Nasr, Samih H. , Dispenzieri, Angela , Kumar, Shaji , Lacy, Martha Q. , Erickson, Stephen B., Cosio, Fernando G., Kapoor, Prashant , Lust, John A., Hayman, Suzanne R. , Zeldenrust, Steven R., Russell, Stephen J. , Dingli, David , Lin, Yi , Lorenz, Elizabeth C. , Zand, Ladan , Kyle, Robert A. , Kourelis, Taxiarchis V, Buadi, Francis K. , Rajkumar, Vincent, Gertz, Morie A. , Fervenza, Fernando C. , Rajkumar, S. Vincent , Gonsalves, Wilson I. , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | August 8, 2016 | Volume: 91 | Issue: 11 | Pages: 1123-1128

10.1002/ajh.24528 | PMID 27501122 Get It

Recent reports suggest that deep hematologic responses to chemotherapy are associated with improved renal outcomes in monoclonal immunoglobulin deposition disease (MIDD). Here we describe the long term outcomes and identify prognostic factors after first line treatment of the largest reported series of patients with MIDD. Between March 1992 and December 2014, 88 patients with MIDD were seen at Mayo Clinic, MN. Renal responses were defined using criteria used for light chain amyloidosis (AL) or those used by the IMWG. Sixty‐one (69%) patients had a GFR < 30 mL/min/1.73 m2 and 16 (18%) were on renal replacement therapy at diagnosis. The interval between albuminuria or elevation in creatinine and MIDD diagnosis was 12 months suggesting a delay in diagnosis. Thirty‐seven patients (42%) had at least a hematologic CR/VGPR. Fifty‐three (60%) received an autologous stem cell transplant (ASCT) or proteasome inhibitor (PI)‐based treatments. Patients receiving ASCT or PI‐based therapies were more likely to achieve at least a hematologic CR/VGPR compared to those receiving other therapies: 66% vs 2%, p < 0.0001. Patients that achieved a hematologic CR were more likely to achieve a renal response (53% vs 24%, p = 0.001). Five year overall and renal survival for the entire cohort was 67% and 57%, respectively. In multivariate analyses, a baseline GFR < 20 mL/min/1.73 m2 and a renal response (using AL or IMWG criteria) were independently predictive of progression to dialysis. This study confirms that deep hematologic responses, best achieved with ASCT or PI‐based therapies, are a prerequisite to achieving renal responses. Am. J. Hematol. 91:1123–1128, 2016. © 2016 Wiley Periodicals, Inc.
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
Ramakrishnan, Vijay , Prasad, Vivek , Kimlinger, Teresa K. , Painuly, Utkarsh , Mukhopadhyay, Bedabrata, Haug, Jessica, Bi, Lintao , Kumar, Shaji , Gomez, Marcus, Kimlinger, Teresa, Gomez, Marcus, Prasad, Vivek, Rajkumar, S. Vincent

Mayo Clinic

Oncotarget | August 3, 2016 | Volume: 7 | Issue: 35 | Pages: 56253-56265

10.18632/oncotarget.11028 | PMID 27494845 Get It

99mTc-methylene diphosphonate single-photon emission computed tomography/computed tomography improves the diagnostic accuracy of osteoid osteoma
Squier, SamuelBrian, Lewis, JacobIan, Accurso, JosephMatthew, Jain, Manoj Kumar, Squier, Samuel Brian, Lewis, Jacob Ian, Accurso, Joseph Matthew, Lewis, Jacob I. , Accurso, Joseph , Jain, Manoj Kumar

Mayo Clinic

Indian Journal of Nuclear Medicine | August 1, 2016 | Volume: 31 | Issue: 4 | Pages: 298-300

10.4103/0972-3919.187459 | PMID 27833319 Get It

We present a case of a 17-year-old football player who had previously received multiple facet joint injections for presumed secondary osteoarthritis. 99 mTc-methylene diphosphonate single-photon emission computed tomography/computed tomography imaging of the cervical spine demonstrated focal increased radiopharmaceutical activity in the right C2 lamina, which was associated with an osteolytic lesion with a central irregular sclerotic nidus. Surgical pathology confirmed an osteoid osteoma.
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII
Kumar, Anita J. , Gimotty, Phyllis A. , Gelfand, Joel M. , Buck, Georgina , Rowe, Jacob M. , Goldstone, Anthony H., Marks, David I. , Litzow, Mark R. , Paietta, Elisabeth , Tallman, Martin S. , Luger, Selina M. , Loren, Alison W. , Fielding, Adele K. , Lazarus, Hillard M.

Mayo Clinic

American Journal of Hematology | July 28, 2016 | Volume: 91 | Issue: 11 | Pages: 1107-1112

10.1002/ajh.24497 | PMID 27468137 Get It

Adults with acute lymphoblastic leukemia (ALL) have a poorer prognosis than children due to a high risk of relapse. One explanation may be variable adherence to dose‐intense chemotherapy. However, little is known about risk factors for delays in therapy and their impact on survival. We conducted an analysis of ECOG 2993/UKALLXII trial to study delays in postremission chemotherapy in adults with newly diagnosed ALL. Logistic regression was used to identify risk factors for a very long delay (VLD, >4 weeks) in start of intensification therapy. Cox regression was used to evaluate the impact of delays on overall survival (OS) and event‐free survival (EFS). We evaluated 1076 Philadelphia chromosome negative (Ph−) patients who completed induction chemotherapy, achieved complete remission, and started intensification. Factors independently associated with VLD included duration of hospitalization (odds ratio [OR] = 1.2, P < 0.001) during Phase I; thrombocytopenia during Phase I (OR = 1.16, P = 0.004) or Phase II (OR 1.13, P = 0.001); chemotherapy dose reductions during Induction Phase I (OR = 1.72, P < 0.014); female sex (OR = 1.53, P = 0.010); Black (OR = 3.24, P = 0.003) and Asian (OR = 2.26, P = 0.021) race; and increasing age (OR = 1.31, P < 0.001). In multivariate Cox regression, patients who underwent allogeneic stem cell transplant (alloHCT) had significantly worse OS (HR 1.4, P = 0.03) and EFS (HR 1.4, P = 0.02) after experiencing a VLD compared to alloHCT patients who experienced ≤4 weeks delay. Specific populations (female, older, Black, and Asian patients) were more likely to experience delays in chemotherapy, as were those with significant toxicity during induction. VLDs in therapy negatively affected outcomes in patients undergoing allografting. Am. J. Hematol. 91:1107–1112, 2016. © 2016 Wiley Periodicals, Inc.
Abstract 2411: Evolution during propagation and treatment of patient-derived triple negative breast cancer xenografts
Kim, Hyunsoo, Kumar, Pooja , Menghi, Francesca , Ananda, Guru, Chen, Henry C., Yang, Yan , Karuturi, Rajesh, Bult, Carol J. , Liu, Edison, Chuang, Jeffrey H., Kim, Hyunsoo, George, Joshy , Mockus, Susan M. , Zhang, Chengsheng , Larson, Nicholas B. , Yang, Yan, Keck, James , Lee, Charles

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 2411-2411

10.1158/1538-7445.am2016-2411 Get It

Abstract Individual tumors, including the aggressive and difficult to treat triple-negative (ER-/PR-/HER2-) breast cancers (TNBCs) are heterogeneous collections of cells with multiple subclonal populations each contributing to the tumor. While subclonal heterogeneity is likely responsible for the development of drug resistance, identification of how tumor cell populations change over time has been difficult, largely because of the challenges in resampling tumor tissue at close time points. Here we quantify tumor evolution in human patient-derived xenografts implanted into NSG mice, which we use to test subclonal heterogeneity as a function of location within a tumor, propagation time, and drug treatment. We used high-depth (∼400x) sequencing of a targeted panel of 358 genes to quantify somatic mutation allele frequencies from 6 spatially-separated and 8 temporally-propagated xenograft samples derived from the same TNBC patient tumors. Samples ranged in age from 2-4 months post-engraftment. Although we observed a few low frequency mutations distinguishing samples, overall we found that allele frequencies of somatic mutations were well-preserved on this time scale. We then generated replicate xenografts from the same patient tumor and treated them respectively with cisplatin, doxorubicin, cyclophosphamide, docetaxel, or vehicle control for 25 days. Although again somatic mutations showed few differences in allele frequency across samples, substantial variations were seen when data were analyzed for copy number alterations. To confirm these effects we repeated the treatments for xenografts derived from two additional TNBC patients. Again we observed strong changes in tumor heterogeneity at the copy number level. This effect was particularly, but not exclusively, apparent in tumors with the greatest response to therapy. We further verified these measurements through Sanger and digital PCR sequencing on the treated mice and other mice in the same cohorts. Using a multi-sample xenograft propagation, dissection, sequencing, and computational analysis protocol, we have shown that tumor subpopulation changes in response to treatment can be quantified and distinguished from spatial or temporal effects, even for treatment time courses as short as 1 month. In triple negative breast cancer these variations are most apparent at the level of copy number variation. Our study demonstrates how patient-derived xenografts can provide detailed resolution of tumor population evolution during the manifestation of resistance. Citation Format: Hyunsoo Kim, Pooja Kumar, Francesca Menghi, Joshy George, Guru Ananda, Susan Mockus, Chengsheng Zhang, Nicholas Larson, Henry C. Chen, Yan Yang, James Keck, R. Krishnamurthy Karuturi, Charles Lee, Carol Bult, Edison Liu, Jeffrey H. Chuang. Evolution during propagation and treatment of patient-derived triple negative breast cancer xenografts. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2411.
Abstract 1260: Polymerase kappa determines the sensitivity of MTH1 inhibitors to cisplatin-resistant cell
Hurley, Rachel M. , Herr, Patric, Koolmeister, Tobias, Jaques, Sylvain, Höglund, Andreas , Scobie, Martin , Kaufmann, Scott H. , Weroha, S. John , Hendrickson, Andrea Wahner, Sanjiv, Kumar , Gad, Helge , Rudd, Sean G. , Herr, Patrick , Calderón‐Montaño, José Manuel , Mortusewicz, Oliver , Burgos‐Morón, Estefanía , Lee, Te‐Chang , Berglund, Ulrika Warpman , Helleday, Thomas , Kaufmann, Scott H

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 1260-1260

10.1158/1538-7445.am2016-1260 Get It

Abstract Resistance is one the main reason for overall decrease in survival of cancer patient treated with cisplatin in different types of cancer. Cisplatin kills cancer cells by various mechanisms, but mainly through formation of inter- and intra stand crosslinks of DNA. Different types of translesion polymerase including Polymerase kappa (POLK) are involved in repair of DNA lesions. We observed high expression levels of POLK in cisplatin resistant bladder and ovarian cancer cells compared to parental cells. Due to its low proof-reading activity POLK can incorporate 8-oxo-dGTP into DNA. The MTH1 protein (Nudix hydrolase- NUDT1) sanitizes oxidized dNTP pools to prevent incorporation of damaged bases during DNA replication. Recently we have generated MTH1 inhibitors that damage the DNA and induce cancer specific cell death through incorporation of more oxidized dNTPs. We found cisplatin resistant bladder cancer cells (NTUB1/P) were more sensitive to MTH1 inhibitors in comparison to parental NTUB1 cells. As POLK is involved in incorporation of 8-oxo-dGTP into DNA, we hypothesized that high expression levels of POLK in cisplatin resistant cells make them more sensitive to MTH1 inhibitors as more 8-oxo-dGTP would be incorporated into DNA, resulting in more DNA damage and cell death in comparison to parental cells. Indeed, we observes higher induction of cleaved-PARP, γH2AX, cleaved-Caspase 3 and more annexin v positive cells in cisplatin resistant NTUB1/P cells in comparison to parental NTUB1 cells upon treatment with MTH1 inhibitors. MTH1 inhibitor also significantly delays the NTUB1/P xenograft tumor growth in comparison to vehicle treatment in immunosuppressive mice. Knocking down POLK in cisplatin resistant NTUB1/P cells by siRNA resulted in decreased incorporation of 8-oxo-dGTP and sensitivity to MTH1 inhibitors compared to non target control cells. Overexpression of POLK in NTUB1 and NTUB1/P cells results in further sensitization to MTH1 inhibitors. In conclusion elevated levels of POLK in cisplatin resistance cells determines increased sensitivity towards MTH1 inhibitors. Thus MTH1 inhibitors can be a potential promising therapy for the treatment of cisplatin resistant tumors in patients. Citation Format: Kumar Sanjiv, Helge Gad, Sean Rudd, Rachel Hurley, Patric Herr, José Manuel Calderón Montaño, Oliver Mortusewicz, Tobias Koolmeister, Sylvain Jaques, Estefanía Burgos Morón, Andreas Hoglund, Te-Chang Lee, Martin Scobie, Scott Kaufmann, John Weroha, Ulrika Warpman Berglund, Andrea Wahner Hendrickson, Thomas Helleday. Polymerase kappa determines the sensitivity of MTH1 inhibitors to cisplatin-resistant cell. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1260.
National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer
Pal, Sumanta K. , Agarwal, Neeraj , Boorjian, Stephen A. , Hahn, Noah M. , Siefker‐Radtke, Arlene O. , Pal, Sumanta Kumar, Boorjian, Stephen Anthony, Clark, Peter E, Plimack, Elizabeth R, Agarwal, Neeraj , Siefker-Radtke, Arlene Odelia , Clark, Peter E. , Plimack, Elizabeth R.

Mayo Clinic

Journal of Clinical Oncology | July 26, 2016 | Volume: 34 | Issue: 27 | Pages: 3346-3348

10.1200/jco.2016.68.1429 | PMID 27458279 Get It

Author response to letter to editor: Hyperinsulinemia adversely affects lung structure and function
Singh, Suchita, Bhatraju, Naveen Kumar , Pattnaik, Bijay , Gheware, Atish , Parameswaran, Praveen Kolumam, Thompson, Michael , Freeman, Michelle, Mabalirajan, Ulaganathan , Gosens, Reinoud , Ghosh, Balaram , Linneberg, Allan , Prakash, Y. S. , Agrawal, Anurag , Pabelick, Christina, Bodas, Manish , Pabelick, Christina M. , Prakash, Y S , Gosens, Reinoud , Bhatraju, Naveen Kumar

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | July 13, 2016 | Volume: 311 | Issue: 1 | Pages: L183-L184

10.1152/ajplung.00227.2016 | PMID 27407082 Get It

Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma
Chakraborty, Rajshekhar , Muchtar, Eli , Kumar, Shaji , Dingli, David , Dispenzieri, Angela , Hayman, Suzanne R. , Kapoor, Prashant , Lacy, Martha Q. , Buadi, Francis K. , Hogan, William J. , Leung, Nelson , Gertz, Morie A. , Muchtar, E , Dispenzieri, Angela , Chakraborty, Rajshekhar , Dingli, David

Mayo Clinic

Leukemia & Lymphoma | July 8, 2016 | Volume: 58 | Issue: 2 | Pages: 308-315

10.1080/10428194.2016.1201572 | PMID 27390076 Get It